Vaxcyte Q3 2026 net loss widens 40% to $297.1 million
- Vaxcyte’s third-quarter 2026 net loss widened 40% year over year to $297.1 million.
- Research and development expenses rose 29% to $270.3 million, primarily due to higher PCV development and manufacturing costs.
- Cash, cash equivalents and investments totaled $2.26 billion at September 30, excluding approximately $1.1 billion raised through October offerings.
- VAX-31 met all prespecified primary endpoints in the pivotal OPUS-1 adult trial, with a safety profile similar to PCV20 and PCV21.
- OPUS-2 and OPUS-3 results are expected in the first half of 2027, supporting a planned biologics license application in early 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870443) on November 04, 2026, and is solely responsible for the information contained therein.